Cytodyne to appeal lawsuit
This article was originally published in The Tan Sheet
Executive Summary
Xenadrine marketer will appeal class action ruling by San Diego state court May 30 that firm's ads for ephedra-containing Xenadrine RFA-1 are false, deceptive. Judge Ronald Styn ordered firm to pay $12.5 mil. to California consumers because it is "money obtained by means of unlawful practice." Ruling maintains Cytodyne's "before and after" testimonies are misleading, exaggerate individual results. In response, firm states "we believe California's false advertising laws are so lax that they literally permit any business that advertises a product to be sued - even when, as here, the plaintiff's lawyer doesn't have an injured or deceived client." Plaintiff's lawyer Todd Macaluso of San Diego-based Macaluso & Associates reportedly also will represent parents of Steve Bechler in suit against Cytodyne...
You may also be interested in...
Cytodyne Products’ Distribution And Sales Rights Licensed To Phoenix Labs
Cytodyne Technologies has licensed the distribution, marketing and sales rights to its products to Apex Fitness Group's Phoenix Labs division, the firms announced June 16
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.